ALK-Abelló A/S (AKBLF)

Market Cap	7.49B +56.1%
Revenue (ttm)	954.84M +12.9%
Net Income	172.96M +40.3%
EPS	0.78 +41.8%
Shares Out	n/a
PE Ratio	43.28
Forward PE	34.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	270
Average Volume	246
Open	35.80
Previous Close	36.10
Day's Range	35.80 - 35.80
52-Week Range	19.90 - 36.14
Beta	0.58
RSI	64.03
Earnings Date	Feb 20, 2026

About ALK-Abelló

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healt...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1923
• Employees: 2,764
• Stock Exchange: OTCMKTS
• Ticker Symbol: AKBLF

Financial Performance

In 2024, ALK-Abelló's revenue was 5.54 billion, an increase of 14.78% compared to the previous year's 4.82 billion. Earnings were 815.00 million, an increase of 67.70%.

Financial numbers in DKK